1281 related articles for article (PubMed ID: 15561674)
1. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
2. Increasing prevalence of thalassemia in America: Implications for primary care.
Sayani FA; Kwiatkowski JL
Ann Med; 2015; 47(7):592-604. PubMed ID: 26541064
[TBL] [Abstract][Full Text] [Related]
3. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Peng CT; Tsai CH; Wu KH
Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
[TBL] [Abstract][Full Text] [Related]
4. Iron and oxidative stress in cardiomyopathy in thalassemia.
Berdoukas V; Coates TD; Cabantchik ZI
Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
[TBL] [Abstract][Full Text] [Related]
5. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
6. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
7. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
8. Iron chelation therapy and thalassemia - an overview.
Chakrabarty P; Rudra S; Hossain MA; Bhuiyan MR; Khaleque MA; Haque MM
Mymensingh Med J; 2011 Jul; 20(3):513-9. PubMed ID: 21804522
[TBL] [Abstract][Full Text] [Related]
9. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
Farmaki K; Tzoumari I; Pappa C
Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
[TBL] [Abstract][Full Text] [Related]
10. New advances in iron chelation therapy.
Cohen AR
Hematology Am Soc Hematol Educ Program; 2006; ():42-7. PubMed ID: 17124038
[TBL] [Abstract][Full Text] [Related]
11. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
12. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
13. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
[TBL] [Abstract][Full Text] [Related]
14. Iron chelation in thalassemia: time to reconsider our comfort zones.
Berdoukas V; Farmaki K; Wood JC; Coates T
Expert Rev Hematol; 2011 Feb; 4(1):17-26. PubMed ID: 21322775
[TBL] [Abstract][Full Text] [Related]
15. Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
Pinto VM; Forni GL
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233561
[TBL] [Abstract][Full Text] [Related]
16. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
[TBL] [Abstract][Full Text] [Related]
17. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
[TBL] [Abstract][Full Text] [Related]
18. Effective iron chelation practice for patients with β-thalassemia major.
Carson SM; Martin MB
Clin J Oncol Nurs; 2014 Feb; 18(1):102-11. PubMed ID: 24476732
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
